Miraculins Announces Launch of Enhanced Website

3/7/2007

WINNIPEG, MANITOBA, Mar 7, 2007 (CCNMatthews via COMTEX News Network) -- 

Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products is pleased to announce the launch of its enhanced corporate website.

Key new features of www.miraculins.com include the integration of additional technology and product information, improvements to content organization and enhancements to navigation.

The site's new design, functionality and content have been strategically chosen to reflect Miraculins' position as a leader in the discovery and development of biomarker diagnostics to improve the overall diagnosis and treatment of cancer.

"The enhanced website is an important component of Miraculins' overall corporate communications strategy", commented Christopher J. Moreau, president and CEO of Miraculins Inc. "We are focused on strengthening our communications with existing and potential investors, while increasing awareness of our Company throughout the financial and investment community, the media and with potential business partners."

"As we continue to develop our pipeline of products and move closer to commercialization of our diagnostics, it is imperative that we provide detailed, up-to-date information about our Company's progress to these audiences," continued Mr. Moreau. "The introduction of our new website provides us with another vehicle to successfully communicate the Miraculins story."

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's B.E.S.T. Platform(TM) utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

Certain information contained in this press release may be forward-looking statements and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

SOURCE: Miraculins Inc.

Miraculins Inc. Sandra Benson Manager, Investor Relations (204) 478-5602 (204) 453-1546 (FAX) Email: sbenson@miraculins.com Website: www.miraculins.com Miraculins Inc. Mr. Christopher J. Moreau President and CEO (204) 453-1408 Email: info@miraculins.com
Copyright (C) 2007 CCNMatthews. All rights reserved.